Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 220(12): 1989-1998, 2019 11 06.
Article in English | MEDLINE | ID: mdl-31412123

ABSTRACT

BACKGROUND: Tuberculosis is caused by Mycobacterium tuberculosis. Recent emergence of multidrug-resistant (MDR) tuberculosis strains seriously threatens tuberculosis control and prevention. However, the role of macrophage multidrug resistance gene MDR1 on intracellular M. tuberculosis survival during antituberculosis drug treatment is not known. METHODS: We used the human monocyte-derived macrophages to study the role of M. tuberculosis in regulation of MDR1 and drug resistance. RESULTS: We discovered that M. tuberculosis infection increases the expression of macrophage MDR1 to extrude various chemical substances, including tuberculosis drugs, resulting in enhanced survival of intracellular M. tuberculosis. The pathway of regulation involves M. tuberculosis infection of macrophages and suppression of heat shock factor 1, a transcriptional regulator of MDR1 through the up-regulation of miR-431. Notably, nonpathogenic Mycobacterium smegmatis did not increase MDR1 expression, indicating active secretion of virulence factors in pathogenic M. tuberculosis contributing to this phenotype. Finally, inhibition of MDR1 improves antibiotic-mediated killing of M. tuberculosis. CONCLUSION: We report a novel finding that M. tuberculosis up-regulates MDR1 during infection, which limits the exposure of M. tuberculosis to sublethal concentrations of antimicrobials. This condition promotes M. tuberculosis survival and potentially enhances the emergence of resistant variants.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B/genetics , Gene Expression Regulation , Macrophages/metabolism , Macrophages/microbiology , Mycobacterium tuberculosis/physiology , Tuberculosis/genetics , Tuberculosis/microbiology , ATP Binding Cassette Transporter, Subfamily B/metabolism , Animals , Antitubercular Agents/pharmacology , Antitubercular Agents/therapeutic use , Disease Models, Animal , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Humans , Macrophages/immunology , Mice , MicroRNAs/genetics , Microbial Viability/drug effects , Mycobacterium tuberculosis/drug effects , Tuberculosis/drug therapy , Tuberculosis/metabolism , Tuberculosis, Pulmonary/genetics , Tuberculosis, Pulmonary/metabolism , Tuberculosis, Pulmonary/microbiology , Tuberculosis, Pulmonary/pathology , Virulence Factors
2.
Mucosal Immunol ; 12(3): 805-815, 2019 05.
Article in English | MEDLINE | ID: mdl-30778118

ABSTRACT

Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB), is the leading killer due to an infectious organism. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only vaccine approved against TB, however, its efficacy against pulmonary TB is poor. While BCG is currently inoculated intradermally, the natural route of M.tb infection is through the lung. Excessive lung pathology caused by pulmonary inoculation of BCG has prevented the use of this immunization route. Here, we show that selective chemical treatment of BCG with petroleum ether removes inflammatory lipids from the bacterial surface while keeping BCG viable. Pulmonary vaccination using this modified BCG attenuated inflammatory responses, prevented immunopathology of the lung, and significantly increased protection against M.tb infection in mice. We further directly linked IL-17A as the responsible contributor of improved immunity against M.tb infection. These results provide evidence that selective removal of cytotoxic lipids from the BCG surface attenuates inflammation and offers a safer and superior vaccine against TB causing less damage post-infectious challenge with M.tb.


Subject(s)
BCG Vaccine/immunology , Inflammation Mediators/immunology , Lipids/immunology , Lung/immunology , Mycobacterium bovis/physiology , Mycobacterium tuberculosis/physiology , Tuberculosis, Pulmonary/immunology , Alkanes/chemistry , Animals , BCG Vaccine/chemistry , Female , Inflammation Mediators/chemistry , Interleukin-17/metabolism , Lipid Metabolism , Lipids/chemistry , Lung/microbiology , Mice , Mice, Inbred C57BL , Vaccination
3.
Front Immunol ; 8: 1561, 2017.
Article in English | MEDLINE | ID: mdl-29201027

ABSTRACT

Activation, recruitment, and effector function of T lymphocytes are essential for control of mycobacterial infection. These processes are tightly regulated in T cells by the availability of l-arginine within the microenvironment. In turn, mycobacterial infection dampens T cell responsiveness through arginase induction in myeloid cells, promoting sequestration of l-arginine within the local milieu. Here, we show T cells can replenish intracellular l-arginine through metabolism of l-citrulline to mediate inflammatory function, allowing anti-mycobacterial T cells to overcome arginase-mediated suppression. Furthermore, T cell l-citrulline metabolism is necessary for accumulation of CD4+ T cells at the site of infection, suggesting this metabolic pathway is involved during anti-mycobacterial T cell immunity in vivo. Together, these findings establish a contribution for l-arginine synthesis by T cells during mycobacterial infection, and implicate l-citrulline as a potential immuno-nutrient to modulate host immunity.

SELECTION OF CITATIONS
SEARCH DETAIL
...